Biotech Company
ProMIS Neurosciences Inc. (TSX:PMN, OTCQB:ARFXF, Forum) on Wednesday announced that it has closed a private placement of 9,560,000 units for gross proceeds of roughly $2,198,800 (CAD). Company President and CEO Elliot Goldstein stated that these funds will - “Allow us to capitalize on the continued interest we are seeing from large pharma in our programs targeting toxic forms of alpha-synuclein for Parkinson's disease (PD) and TDP43 for ALS (amyotrophic lateral sclerosis).”
To find out more, click
here.
ProMIS recently stated that Company management will attend the NobleCon15 and the Cantech Investment Conferences to provide overviews of its drug discovery and development programs for Alzheimer's disease, Parkinson's disease and ALS (amyotrophic lateral sclerosis). Management will also participate on discussion panels on Monday, January 28, and Tuesday, January 29, 2019, respectively.
FULL DISCLOSURE: ProMIS Neurosciences Inc. is a client of Stockhouse Publishing.